208124-34-9

Basic information

• Product Name: N-[2-(3,5-Difluorophenyl)acetyl]-L-alanine
• Synonyms: N-[2-(3,5-Difluorophenyl)acetyl]-L-alanine;3,5-Difluorophenylacetyl-(S)-alanine;N-[(3,5-Difluorophenyl)acetyl]-(S)-alanine
• CAS NO: 208124-34-9
• Molecular Formula: C₁₁H₁₁F₂NO₃
• Molecular Weight: 243.2067464
• Product Categories: Amino Acids & Derivatives;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 208124-34-9.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• Solubility: Dichloromethane, Ethyl Acetate, Methanol
• CAS DataBase Reference: N-[2-(3,5-Difluorophenyl)acetyl]-L-alanine(CAS DataBase Reference)
• NIST Chemistry Reference: N-[2-(3,5-Difluorophenyl)acetyl]-L-alanine(208124-34-9)
• EPA Substance Registry System: N-[2-(3,5-Difluorophenyl)acetyl]-L-alanine(208124-34-9)

Safety Data

• Hazardous Substances Data: 208124-34-9(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

Intermediate in the production of antialzheimer agents.

Upstream product

• 157033-24-4 3,5-difluorophenylacetyl chloride 
• 56-41-7 L-alanin 
• 649736-97-0 N-3,5-difluoro-phenylacetyl-(S)-alanine benzyl ester 
• 680230-04-0 (S)-2-[(3,5-difluorophenyl)acetamido]propanoic acid methyl ester 
• 105184-38-1 3,5-difluorophenyl acetic acid 
• 867021-89-4 N-(3,5-difluorophenylacetyl)-L-alanine tert-butyl ester 

Downstream Products

• 762289-60-1 N₁-[(3R,7S)-1-cyclopentyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-N₂-[(3,5-difluorophenyl)acethyl]-L-alaninamide 
• 762289-69-0 N₁-[(3R,7S)-1-isobutyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-N₂-[(3,5-difluorophenyl)acetyl]-L-alaninamide 
• 762289-33-8 C₂₇H₂₉F₂N₃O₃ 
• 209985-53-5 3-(N'-(3,5-difluorophenylacetyl)-L-alaninyl)amino-5-phenyl-2,3-dihydro-1-ethyl-1H-1,4-benzodiazepin-2-one 
• 1026946-14-4 3-(N'-(3,5-difluorophenylacetyl)-L-alaninyl)amino-γ-butyrolactam 
• 209984-27-0 3-(N'-(3,5-difluorophenylacetyl)-L-alaninyl)amino-1-ethyl-5,5-dimethyl-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one 
• 209983-05-1 5-[N'-(3,5-difluorophenylacetyl)-L-alaninyl]amino-5,7-dihydro-6H-dibenzo[a,c]cyclohepten-6-ol 
• 209983-03-9 1-(N'-(3,5-difluorophenylacetyl)-L-alaninyl)-amino-1,2,3,4-tetrahydro-2-naphthol 
• 209983-14-2 4-(N'-(3,5-difluorophenylacetyl)-L-alaninyl)amino-1,1-dimethyl-3-isochromanone 
• 209983-65-3 4-(N'-(3,5-difluorophenylacetyl)-L-alaninyl)amino-7-benzyl-1,2,3,4-tetrahydroisoquinolin-3-one 
• 209983-41-5 4-(N'-(3,5-difluorophenylacetyl)-L-alaninyl)amino-1-phenyl-1,2,3,4-tetrahydroisoquinolin-3-one 
• 209983-44-8 4-(N'-(3,5-difluorophenylacetyl)-L-alaninyl)amino-2-phenethyl-1,2,3,4-tetrahydroisoquinolin-3-one 
• 209983-45-9 4-(N'-(3,5-difluorophenylacetyl)-L-alaninyl)amino-2-methyl-1,2,3,4-tetrahydroisoquinolin-3-one 

Relevant articles and documents

Formation of Non-Natural α,α-Disubstituted Amino Esters via Catalytic Michael Addition

The enolate monoanion of amino esters is explored, and the first catalytic Michael addition of α-amino esters is demonstrated. These studies indicate that the acidity of the αC-H is the primary factor determining reactivity. Thus, polyfluorophenylglycine amino esters yield novel α-amino esters in the presence of a catalytic amount of a guanidine-derived base and Michael acceptors. Reactivity requires an acidic N-H, which is accomplished using common protecting groups such as N-Bz, N-Boc, and N-Cbz. Calculations and labeling experiments provide insight into the governing principles in which a key C-to-N proton transfer occurs, resulting in an expansion of the scope to include a number of natural amino esters. The study culminates with a late-stage functionalization of peptidic γ-secretase inhibitor, DAPT.

Synthesis of a tetrahydroimidazo[2',1':2,3]thiazolo[5,4-c]pyridine derivative with Met inhibitory activity

A straightforward synthesis of the Met antagonist JLK1360 involving an alkylationcyclocondensation process using aminothiazole 1 and nitrophenacyl bromide 2, reduction of the nitro group, and coupling of the resulting tetracyclic aniline 5 with an appropr

CHEMICAL COMPOUNDS

The invention provides a new method for treating disorders associated with activation of the Notch signal transduction pathway comprising administering an effective amount of a compound of Formula (I), in free form or in a pharmaceutically acceptable salt